Public consultation on the post-market review of medicines for smoking cessation
Page last updated: 9 July 2021
Draft Report to the Pharmaceutical Benefits Advisory Committee (PBAC) for the Post-market Review of medicines for smoking cessation
Public Consultation: 7 June 2021 to 5:00 pm AEST 2 July 2021
The Call for Submissions on the Draft Report for the Post-market Review of medicines for smoking cessation closed on 2 July 2021. The department appreciates the contribution of all organisations and individuals who made a submission.
The Draft Review Report is provided in five parts, in DOCX and PDF format below. In-confidence information in the Draft Review Report has been redacted.
- Report Summary (PDF 1308KB) - (Word 109KB)
- Background (PDF 1384KB) - (Word 183KB)
- Section 1: Term of Reference (ToR) 1 (PDF 2166KB) - (Word 739KB)
- Section 2: Term of Reference (ToR) 2 (PDF 2156KB) - (Word 314KB)
- Section 3: Term of Reference (ToR) 3 (PDF 11062KB) - (Word 6809KB)
Accessibility
The documents on this page may not be accessible. If you need assistance please email the Review Secretariat.
Stakeholder Forum
A Stakeholder Forum was held via webinar on Thursday 3 December 2020. Consumers, clinicians and peak bodies who have an interest in smoking cessation, and pharmaceutical sponsors who have a current PBS medicine listing for a smoking cessation therapy, were invited to participate in the forum.
A summary of the Stakeholder Forum and the presentation slides are provided below.
- Smoking Cessation Review Stakeholder Forum Summary (Word 59KB)
- Smoking Cessation Review Stakeholder Forum Summary (PDF 980KB)
- Smoking Cessation Review Stakeholder Forum Presentation Slides (PowerPoint 257KB)
The Department appreciates the contribution of all organisations and individuals who attended the forum.
Public Submissions addressing the Review
The call for submissions addressing the Review and final Terms of Reference closed on 01 May 2020. The Department appreciates the contribution of all organisations and individuals who made a submission.
Public Submissions on the Draft Terms of Reference
The call for submissions addressing the draft Terms of Reference (ToR) for the Post‑market review of medicines for smoking cessation closed on 25 November 2019. The Department appreciates the contribution of all organisations and individuals who made a submission.
Privacy
Unless otherwise requested, all submissions to the Review will be published on this page.
The Department of Health will not publish submissions, or parts of submissions, which contain personal information, offensive language, potentially defamatory material or copyright infringing material.
Responsibility for copyright in submissions resides with the author(s), not with the Department of Health.
All submissions will be converted to Portable Document Format (PDF) for publication and may have a different appearance to the document that was submitted.
Your submission and contact details will be stored in accordance with the Privacy Act 1988 and the Archives Act 1983. Should you have any concerns about the storage of your submission, or if you wish to gain access to make a correction, please contact the Review Secretariat. A copy of the Department’s privacy policy is available on request. If you wish to make a complaint about the handling of your private information, you may contact the Department of Health Privacy Contact Officer and, if unsatisfied with the response, you may submit a complaint to the Office of the Australian Information Commissioner.
Disclaimer
- The views expressed in submissions published on this website are solely those of the contributing authors or organisations.
- The Commonwealth accepts no responsibility for the completeness or accuracy of any information contained in the submissions.
- The Commonwealth makes no representations about the suitability of the information for any particular purpose. Users of the information must make their own inquiries and assessments about those matters or seek independent advice.
- Submissions are published on the understanding that the contributing authors or organisations have copyright in the submissions either by way of ownership or a licence. They retain their copyright, and by making submissions they licence the Commonwealth to publish the submissions, unless a party when making a submission has requested that it be kept confidential and the Commonwealth clearly agrees that the submission will be kept confidential.
Table of submissions addressing the draft Terms of Reference
Submission |
Author Name |
Document Link |
Date received |
---|---|---|---|
1 |
The Society of Hospital Pharmacists of Australia |
21/11/2019 |
|
2 |
Lung Foundation Australia |
22/11/2019 |
|
3 |
Cancer Council Australia |
25/11/2019 |
|
4 |
Alfred Health |
25/11/2019 |
|
5 |
Quit Victoria (“Quit”) and the Australian Council on Smoking and Health (ACOSH) |
25/11/2019 |
|
6 |
National Aboriginal Community Controlled Health Organisation (NACCHO) |
25/11/2019 |
|
7 |
Pharmaceutical Society of Australia (PSA) |
25/11/2019 |
|
8 |
The Thoracic Society of Australia and New Zealand (TSANZ) |
27/11/2019 |
|
9 |
The Royal Australian College of General Practitioners Ltd (RACGP) |
27/11/2019 |
Table of submissions addressing the Review
Submission |
Author Name |
Document Link |
Date received |
---|---|---|---|
1 |
Alfred Health |
28/04/2020 |
|
2 |
The Australian Council on Smoking and Health (ACOSH), Cancer Council Australia (CCA), Lung Foundation Australia, Quit and the Victorian Health Promotion Foundation (VicHealth) |
30/04/2020 |
|
3 |
Lung Foundation Australia |
01/05/2020 |
|
4 |
National Aboriginal Community Controlled Health Organisation (NACCHO) |
01/05/2020 |
|
5 |
Perrigo Australia |
01/05/2020 |
|
6 |
Pfizer Australia Pty Ltd |
01/05/2020 |
|
7 |
Royal Australian College of General Practitioners (RACGP) |
01/05/2020 |
|
8 |
The Thoracic Society of Australia and New Zealand (TSANZ) |
01/05/2020 |
|
9 |
NSW Ministry of Health |
04/05/2020 |
|
10 |
Australian College of Nursing (ACN) |
05/05/2020 |
|
11 |
The Society of Hospital Pharmacists of Australia (SHPA) |
15/05/2020 |